With the approval of exenatide in 2005, physicians had a new class of hypoglycemic agents available for the treatment of type 2 diabetes—the glucagon-like peptide-1 receptor agonists (or GLP-1 receptor agonists). As of this writing, there are seven drugs in this class available in the United States. In addition to demonstrating either cardiovascular risk neutrality or overt benefit, as now mandated by the United States Food and Drug Administration (FDA), many of these drugs have other, unexpected actions. It is our goal to outline these actions, some beneficial, some not. We have reviewed English-language articles in this area, not for an exhaustive study, but rather a broad search to define current understanding and perhaps generate further investigation.
Get full access to this article
View all access options for this article.
References
1.
CreutzfeldtW. The [pre-] history of the incretin concept. Regul Pept, 2005; 128:87–91.
2.
StarlingEH. The chemical correlation of the functions of the body. I. The chemical control of the functions of the body. Lancet, 1905; 2:339–341.
3.
StarlingEH. The chemical correlation of the functions of the body. II. The chemical reflexes of the alimentary tract. Lancet, 1905; 2:423–425.
4.
StarlingEH. The chemical correlation of the functions of the body. III. The chemical reflexes of the alimentary tract. Lancet, 1905; 2:501–503.
5.
StarlingEH. The chemical correlation of the functions of the body. IV. The chemical correlations involving growth of organs. Lancet, 1905; 2:579–583.
6.
La BarreJ. Sur les possibilites d'un traitement du diabete par l'incretine [On the possibilities of a treatment of diabetes by incretin]. Bull Acad R Med Belg, 1932; 12:620–634.
7.
CreutzfeldtW. The entero-insular axis in type 2 diabetes—Incretins as therapeutic agents. Exp Clin Endocrinol Diabetes, 2001; 109(Suppl 2):S288–S303.
8.
NauckMA, MeierJJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab, 2018; 20(Suppl 1):5–21.
9.
ChristelCM, DeNardoDF, SecorSM. Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum). J Exp Biol, 2007; 210:3430–3439.
10.
ChristelCM, DenardoDF. Release of exendin-4 is controlled by mechanical action in Gila monsters, Heloderma suspectum. Comp Biochem Physiol A Mol Integr Physiol, 2006; 143:85–88.
11.
ChristelCM, DenardoDF. Absence of exendin-4 effects on postprandial glucose and lipids in the Gila monster, Heloderma suspectum. J Comp Physiol B, 2007; 177:129–134.
12.
RaufmanJP, SinghL, SinghG, et al.Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem, 1992; 267:21432–21437.
13.
MalhotraR, SinghL, EngJ, et al.Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept, 1992; 41:149–156.
14.
ThorensB, PorretA, BühlerL, et al.Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes, 1993; 42:1678–1682.
15.
EganJM, ClocquetAR, ElahiD. The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab, 2002; 87:1282–1290.
16.
Exendin-4: Fromlizard to laboratory⋯and beyond. Accessed at www.nia.nih.gov/news/exendin-4-lizard-laboratory-and-beyond on August 28, 2018.
17.
ChiaCW, EganJM. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes, 2009; 2:37.
18.
KimW, EganJM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev, 2008; 60:470–512.
19.
Ruiz-GrandeC, AlarconC, AlcantaraA, et al.Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res, 1993; 25:612–616.
20.
PackerM. Leptin-aldosterone-neprilysin axis: Identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation, 2018; 137:1614–1631.
21.
GuptaV. Glucagon-like peptide-1 analogues: An overview. Indian J Endocrinol Metab, 2013; 1793:413–421.
22.
ChiaCW, EganJM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab, 2008; 93:3703–3716.
23.
DoyleME, EganJM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther, 2007; 113:546–593.
24.
Suarez-PinzonWL, LakeyJR, RabinovitchA. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant, 2008; 17:631–640.
25.
TahraniAA, BarnettAH, BaileyCJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol, 2016; 12:566–592.
26.
Lixisenatide. Accessed at micromedexsolutions.com on August 28, 2018.
27.
Liraglutide. Accessed at micromedexsolutions.com on October 2, 2018.
28.
EdwardsCM, StanleySA, DavisR, et al.Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab, 2001; 81:E155–E161.
29.
DegnKB, JuhlCB, SturisJ, et al.One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 2004; 53:1187–1194.
30.
MeierJJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol, 2012; 8:728–742.
31.
MontoriVM, Rodriguez-GutierrezR. The triumph of innovation and the hard work of caring for patients with diabetes. Ann Intern Med, 2016; 164:127–128.
32.
McCarthyM. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner. BMJ, 2015; 351:h6702.
33.
MadsbadS. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab, 2016; 18:317–332.
34.
LingvayI, DesouzaCV, LalicKS, et al.A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care, 2018; 41:1926–1937.
35.
PratleyRE, ArodaVR, LingvayI, et al.SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol, 2018; 6:275–286.
36.
[No authors listed]. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods, and baseline results. Diabetes, 1970; 19:747–783.
37.
[No authors listed]. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes, 1970; 19:787–830.
38.
Guidance for industry: Diabetes mellitus—Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed at www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation on October 11, 2018.
39.
MarsoSP, DanielsGH, Brown-FrandsenK, et al.LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375:311–322.
40.
PfefferMA, ClaggettB, DiazR, et al.ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med, 2015; 373:2247–2257.
41.
MarsoSP, BainSC, ConsoliA, et al.SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 2016; 375:1834–1844.
42.
HolmanRR, BethelMA, MentzRJ, et al.EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2017; 377:1228–1239.
43.
HernandezAF, GreenJB, JanmohamedS, et al.Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. Lancet, 2018; 392:1519–1529.
44.
GersteinHC, ColhounHM, DagenaisGR, et al.REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab, 2018; 20:42–49.
45.
FerdinandKC, BotrosFT, AtissoCM, et al.Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 2016; 15:38.
46.
DaviesMJ, D'AlessioDA, FradkinJ, et al.Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018; 41:2669–2701.
47.
WeiY, MojsovS. Tissue-specific expression of the human receptor for glucagon-like peptide -1: Brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett, 1995; 358:219–224.
48.
BullockBP, HellerRS, HabenerJF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology, 1996; 137:2968–2978.
49.
NystromT, GutniakMK, ZhangQ, et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab, 2004; 287:E1209–E1215.
50.
BanK, Noyan-AshrafMH, HoeferJ, et al.Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008; 117:2340–2350.
51.
XiaoYF, NikolskayaA, JayeDA, et al.Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol, 2011; 10:6.
52.
RoseBA, ForceT, WangY. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev, 2010; 90:1507–1546.
53.
ChangG, ZhangD, YuH, et al.Cardioprotective effects of exenatide against oxidative stress-induced injury. Int J Mol Med, 2013; 32:1011–1020.
54.
Vila PetroffMG, EganJM, WangX, et al.Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res, 2001; 89:445–452.
55.
NikolaidisLA, ElahiD, HentoszT, et al.Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004; 110:955–961.
56.
LiS, WuH, HanD, et al.ZP2495 Protects against myocardial ischemia/reperfusion injury in diabetic mice through improvement of cardiac metabolism and mitochondrial function: The possible involvement of AMPK-FoxO3a signal pathway. Oxid Med Cell Longev, 2018; 2018:6451902.
57.
RobinsonLE, HoltTA, ReesK, et al.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open, 2013; 3;pii:e001986. DOI: 10.1136/bmjopen-2012-001986.
58.
EdwardsCM, ToddJF, GhateiMA, et al.Subcutaneous glucagon-like peptide-1 (7–36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci, 1998; 95:719–724.
59.
CerielloA, NovialsA, CanivellS, et al.Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, anti-inflammatory, and antioxidant action in type 2 diabetes. Diabetes Care, 2014; 37:1938–1943.
60.
GillA, HoogwerfBJ, BurgerJ, et al.Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol, 2010; 9:6.
61.
LovshinJA, ZinmanB. Blood pressure-lowering effects of incretin-based diabetes therapies. Can J Diabetes, 2014; 38:364–371.
JojimaT, UchidaK, AkimotoK, et al.Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis, 2017; 261:44–51.
64.
ChaiW, FuZ, AylorKW, et al.Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats. Am J Physiol Endocrinol Metab, 2016; 311:E640–E648.
65.
ZhanJK, TanP, WangYJ, et al.Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway. Cardiovasc Diabetol, 2014; 13:153.
66.
PujadasG, DruckerDJ. Vascular biology of glucagon receptor superfamily peptides: Mechanistic and clinical relevance. Endocr Rev, 2016; 37:554–583.
67.
GarczorzW, Gallego-ColonE, KosowskaA, et al.Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation. Cardiovasc Ther, 2018; 36. DOI: 10.1111/1755-5922.12317.
68.
GokeR, LarsenPJ, MikkelsenJD, et al. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites Eur J Neurosci, 1995; 7:2294–2300.
69.
JinSL, HanVK, SimmonsJG, et al.Distribution of glucagon like peptide I (GLP-I), glucagon, and glicentin in the rat brain: An immunocytochemical study. J Comp Neurol, 1988; 271:519–532.
70.
GallwitzB. Anorexigenic effects of GLP-1 and its analogues. Handb Exp Pharmacol, 2012; 209:185–207.
71.
SisleyS, Gutierrez-AguilarR, ScottM, et al.Neuronal GLP1R mediates liraglutide anorectic but not glucose-lowering effect. J Clin Invest, 2014; 124:2456–2463.
72.
Ten KulveJS, VeltmanDJ, van BloemendaalL, et al.Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. J Endocrinol, 2016; 229:1–12.
73.
CalsolaroV, EdisonP. Novel GLP-1 (glucagon-like peptide-1) analogues and insulin in the treatment for Alzheimer's disease and other neurodegenerative diseases. CNS Drugs, 2015; 29:1023–1039.
74.
HolscherC. Central effects of GLP-1: New opportunities for the treatments of neurodegenerative diseases. J Endocrinol, 2014; 221:T31–T41.
75.
McCleanPL, ParthasarthyV, FaivreE, et al.Diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci, 2011; 31:6587–6594.
76.
Aviles-OlmosI, DicksonJ, KefalopoulouZ, et al.Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest, 2013; 123:2730–2736.
77.
Barreto-ViannaARC, AguilaMB, Mandarim-de-LacerdaCA. Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. Metab Brian Dis, 2017; 32:1735–1745.
78.
LarssonM, LietzauG, NathansonD, et al.Diabetes negatively affects cortical and striatal GABAergic neurons: An effect hat is partially counteracted by exendin-4. Biosci Rep, 2016; 36:pii:e00421.
79.
LietzauG, NystromT, OstensonCG, et al.Type 2 diabetes-induced neuronal pathology in piriform cortex of the rat is reversed by the GLP-1 agonist exendin-4. Oncotarget, 2016; 7:5865–5876.
80.
FengP, ZhangX, LiD, et al.Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 2018; 133:385–394.
81.
JerlhagE. GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology, 2018; 136:343–349.
82.
ZhengSL, RoddickAJ, Aghar-JaffarR, et al.Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and meta-analysis. JAMA, 2018; 319:1580–1591.
83.
O'NeilPM, ArodaVR, AstrupA, et al.Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab, 2017; 19:1529–1536.
84.
GambleJM, ChibrikovE, MidodziWK, et al.Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: A cohort study using the UK Clinical Practice Research Datalink. BMJ Open, 2018; 8:e023830.
85.
MannJFE, ØrstedDD, Brown-FrandsenK, et al.LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med, 2017; 377:839–848.
86.
MuskietMHA, TonneijckL, HuangY, et al.Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: An exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol, 2018; 6:859–869.
87.
PykeC, HellerRS, KirkRK, et al.GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 2014; 155:1280–1290.
88.
ShiJX, HuangQ. Glucagon-like peptide-1 protects mouse podocytes against high glucose-induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro. Mol Med Rep, 2018; 18:1789–1797.
89.
ZhouSJ, BaiL, LvL, et al.Liraglutide ameliorates renal injury in streptozotocin-induced rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway. Mol Med Rep, 2014; 10:2587–2594.
90.
GutzwillerJP, TschoppS, BockA, et al.Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant men. J Clin Endocrinol Metab, 2004; 89:3055–3061.
91.
MuskietMHA, SmitsMM, MorsinkLM, et al.The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol, 2014; 10:88–103.
92.
NauckMA, NiedereichholzU, EttlerR. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol, 1997; 273:E981–E988.
93.
SchirraJ, KuwertP, WankU, et al.Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians, 1997; 109:84–97.
94.
D’ AlessioD.Intestinal hormones and regulation of satiety: The case of CCK, GLP-1, PYY and Apo A-IV. JPEN J Parenter Enteral Nutr, 2008; 32:567–568.
95.
BaggioLL, HuangQ, BrownTJ, et al.A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 R-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes, 2004; 53:2492–2500.
96.
UccellatoreA, GenoveseS, DicembriniI, et al.Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists. Diabetes Ther, 2015; 6:239–256.
97.
NakataniY, MaedaM, MatsumuraM, et al.Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab, 2017; 43:430–437.
98.
BroideE, BlochO, Ben-YehudahG, et al.GLP-1 receptor is expressed in human stomach mucosa: Analysis of its cellular association and distribution within gastric glands. J Histochem Cytochem, 2013; 61:649–658.
99.
LuZ, YeungCK, LinG, et al.Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret. Auton Neurosci, 2017; 202:122–135.
100.
KanoskiSE, RupprechtLE, FortinSM, et al.The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology, 2012; 62:1916–1927.
101.
ZhaoL, ChenY, XiaF, et al.A glucagon-like peptide-1 receptor agonist lowers weight by modulating the structure of gut microbiota. Front Endocrinol (Lausanne), 2018; 9:233.
102.
CaoX, ZhouX, LiuXM, et al.Liraglutide alters DPP4 in the circumvallate papillae of type 2 diabetic rats. J Mol Endocrinol, 2016; 57:13–21.
103.
MartinB, DotsonCD, ShinYK, et al.Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci, 2009; 1170:98–101.
104.
ElashoffM, MatveyenkoAV, GierB, et al.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141:150–156.
105.
EganAG, BlindE, DunderK, et al.Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med, 2014; 370:794–797.
106.
JensenTM, SahaK, SteinbergWM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care, 2015; 38:1058–1066.
107.
LiL, ShenJT, BalaMM, et al.Incretin therapy and risk of pancreatitis in type 2 diabetes mellitus: Systematic review of randomized and non-randomized studies. Value Health, 2014; 17:A740–A741.
108.
AlvesC, Batel-MarquesF, MacedoAF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer. Diabetes Res Clin Pract, 2012; 98:271–284.
109.
VangoitsenhovenR, MathieuC, Van der SchuerenB. GLP1 and cancer: Friend or foe?. Endocr Relat Cancer, 2012; 19:F77–F88.
110.
NachnaniJS, BulchandaniDG, NookalaA, et al.Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia, 2010; 53:153–159.
111.
NauckMA, JensenTJ, RosenkildeC, et al.LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: Results from the LEADER randomised trial. Diabetes Care, 2018; 41:1663–1671.
112.
LangloisA, MuraC, BietigerW, et al.In vitro and in vivo investigation of the angiogenic effects of liraglutide during islet transplantation. PLoS One, 201614; 11:e0147068.
113.
LangloisA, DalS, VivotK, et al.Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties. Br J Pharmacol, 2016; 173:3443–3453.
114.
ValverdeI, MoralesM, ClementeF, et al.Glucagon-like peptide 1: A potent glycogenic hormone. FEBS Lett, 1994; 349:313–316.
115.
DardevetD, MooreMC, NealD, et al.Insulin-independent effects of GLP-1 on canine liver glucose metabolism: Duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab, 2004; 287:E75–E81.
116.
AndersenDK. Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas, 2007; 35:1–15.
117.
EganJM, MeneillyGS, HabenerJF, et al.Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab, 2002; 87:3768–3773.
118.
VellaA, ShahP, ReedAS, et al. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia, 2002; 45:1410–1415. Erratum in: Diabetologia 2003;45:1589.
119.
VellaA, ShahP, BasuR, et al.Effect of glucagon-like peptide 1(7–36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes, 2000; 49:611–617.
120.
VellaA, RizzaRA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res, 2004; 36:830–836.
121.
DingX, SaxenaNK, LinS, et al.Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006; 43:173–181.
122.
GuptaNA, KolachalaVL, JiangR, et al.The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol, 2012; 181:1693–1701.
123.
ArmstrongMJ, GauntP, AithalGP, et al.LEAN Trial Team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016; 387:679–690.
124.
ArmstrongMJ, HullD, GuoK, et al.Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol, 2016; 64:399–408.
125.
GastaldelliA, MarchesiniG. Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. J Hepatol, 2016; 64:262–264.
126.
Pi-SunyerX, AstrupA, FujiokaK, et al.A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med, 2015; 373:11–22.
127.
KellerJ, TrautmannME, HaberH, et al.Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept, 2012; 179:77–83.
128.
SmitsMM, TonneijckL, MuskietMH, et al.Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab, 2016; 18:1217–1225.
129.
VilsbøllT, BainSC, LeiterLA, et al.Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab, 2018; 20:889–897.
130.
DourosA, FilionKB, YinH, et al.Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care, 2018; 41:2330–2338.
GierB, ButlerPC, LaiCK, et al.Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab, 2012; 97:121–131.
133.
LunatiME, GranciniV, ColomboC, et al.Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of liraglutide treatment. Metabolism, 2016; 65:1–6.
134.
HegedüsL, MosesAC, ZdravkovicM, et al.GLP-1 and calcitonin concentration in humans: Lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab, 2011; 96:853–860.
135.
YamadaC, YamadaY, TsukiyamaK, et al.The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology, 2008; 149:574–579.
136.
Lecka-CzernikB. Safety of anti-diabetic therapies on bone. Clin Rev Bone Miner Metab, 2013; 11:49–58.
137.
Liraglutide New Drug Application. FDA Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee. June 20, 2017. Accessed at www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm563334.pdf on April 3, 2019.
138.
HicksBM, YinH, YuOH, et al.Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: Population based cohort study using the UK Clinical Practice Research Datalink. BMJ, 2016; 355:i5340.
139.
Fidan-YaylalıG, DodurgaY, SeçmeM, et al.Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol, 2016; 37:2647–2653.
140.
ZhaoW, ZhangX, ZhouZ, et al.Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression. Mol Med Rep, 2018; 17:5202–5212.
141.
LiXN, BuHM, MaXH, et al.Glucagon-like peptide-1 analogues inhibit proliferation and increase apoptosis of human prostate cancer cells in vitro. Exp Clin Endocrinol Diabetes, 2017; 125:91–97.
142.
KoehlerJA, KainT, DruckerDJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology, 2011; 152:3362–3372.
143.
WenjingH, ShuangY, WeisongL, et al.Exendin-4 does not modify growth or apoptosis of human colon cancer cells. Endocr Res, 2017; 42:209–218.
144.
KosowskaA, Gallego-ColonE, GarczorzW, et al.Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect, 2017; 6:856–865.
145.
KandaR, HiraikeH, Wada-HiraikeO, et al.Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer, 2018; 18:657.
146.
IqbalA, IqbalA. GLP-1 receptor agonists and cancers. Acta Sci Cancer Biol, 2018; 2:21–27.
